These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 2928808)

  • 21. [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
    Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 May; 20(7):907-14. PubMed ID: 8489297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acute myelogenous leukemia associated with severe esophageal stricture after chemotherapy].
    Yata K; Yamada O; Iwato K; Kyo T; Otsuki T; Nakanishi H; Suetsugu Y; Mikami M; Wada H; Yawata Y; Sugihara T
    Rinsho Ketsueki; 2002 Jan; 43(1):41-3. PubMed ID: 11868364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
    Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
    Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
    [No Abstract]   [Full Text] [Related]  

  • 25. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
    Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
    Saikia TK; Bakshi A; Bhagwat R; Tawde S; Nair R; Nair CN; Parikh PM
    Natl Med J India; 2005; 18(1):12-5. PubMed ID: 15835484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
    Colla S; Sammarelli G; Crugnola M; Ascani S; Sabbatini E; Bonomini S; Hojden M; Craviotto L; De Celis I; Morandi F; Caramatti C; Rizzoli V; Giuliani N
    Eur J Haematol; 2004 May; 72(5):361-5. PubMed ID: 15059073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idarubicin: an anthracycline antineoplastic agent.
    Cersosimo RJ
    Clin Pharm; 1992 Feb; 11(2):152-67. PubMed ID: 1551297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
    Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E
    Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
    Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
    Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
    [No Abstract]   [Full Text] [Related]  

  • 34. Lineage switch and multilineage involvement in two cases of pH chromosome-positive acute leukemia: evidence for a stem cell disease.
    Cuneo A; Balboni M; Piva N; Carli MG; Tomasi P; Previati R; Negrini M; Scapoli G; Spanedda R; Castoldi G
    Haematologica; 1994; 79(1):76-82. PubMed ID: 15378954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
    Keating MJ; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich EJ
    Leukemia; 1992; 6 Suppl 2():78-80. PubMed ID: 1578950
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of relapsed and refractory acute myeloid leukemia in adults.
    Lazzarino M; Morra E; Alessandrino EP; Merante S; Bernasconi P; Bonfichi M; Caldera D; Bernasconi C
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():121-3. PubMed ID: 2653487
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination chemotherapy with DATV regimen in treatment of adult acute nonlymphocytic leukemia.
    Lou FD; Zhou Q; Liu HC; Meng FY; Wang YZ
    Chin Med J (Engl); 1993 Nov; 106(11):876-8. PubMed ID: 8143502
    [No Abstract]   [Full Text] [Related]  

  • 40. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.